Veradermics Stock Just Popped 45% On Hair Loss Trial Data

A small biopharma you may have never heard of just had one of the bigger move-makers of Monday's trading session, and it's all about hair loss.

Veradermics, ticker MANE on the New York Stock Exchange, jumped roughly 45% Monday after the company released positive late-stage trial data for an oral hair loss pill. Shares traded near $97 at one point.

What The Trial Showed

The drug is called VDPHL01. It's a once- or twice-daily extended-release pill version of minoxidil, the same active ingredient most men know as Rogaine, but in a formulation built specifically for hair loss instead of borrowed from a heart medication.

The Phase 2/3 trial enrolled 519 men with mild-to-moderate pattern baldness, and the numbers came in clean:

• Patients on the twice-daily dose grew an average of 33 hairs per square centimeter at six months.
• Patients on the once-daily dose grew 30.
• Placebo patients grew about 7.
• 86% of twice-daily patients reported some improvement on a standard hair loss scale, versus 36% on placebo.
• No treatment-related serious adverse events and no cardiac issues, one of the historical risks of oral minoxidil.

The drug also showed results as early as month two, the earliest data point measured. That's fast for a class that usually takes longer to kick in.

The Market Opportunity

Pattern hair loss is the biggest aesthetic condition in the U.S. by patient count, with around 80 million people affected, including roughly 50 million men and 30 million women.

It's been almost three decades since the FDA approved a new prescription drug for it. The aesthetics market is projected to hit roughly $30 billion by 2028, and Veradermics CEO Reid Waldman called the trial a "defining milestone for the hair loss community."

Worth noting: Veradermics priced a $256 million IPO in February of this year, so this is the kind of result early investors had been waiting on.

Why The Stock Moved So Hard

The market for oral minoxidil today runs through off-label prescriptions, with doctors writing scripts for low-dose pills designed for blood pressure. That works, but it's clunky and carries cardiac concerns.

VDPHL01 was designed from the ground up to deliver minoxidil at steady levels, avoiding the peak doses that drive heart side effects. The Phase 2/3 data confirmed that thesis, with adverse event rates similar to placebo.

Combine clean efficacy with a clean safety profile, in a market with no new prescription option in 30 years, and you get a 45% pop.

What To Watch

Veradermics has a second Phase 3 male trial - Study 304 - wrapping up later this year, with topline results expected in the second half of 2026. A separate Phase 2/3 trial is currently recruiting women.

If both clear, VDPHL01 could be the only FDA-approved oral, non-hormonal pattern hair loss drug for both men and women. That's a clean shot at a market that's been begging for a new option.

Wall Street paid attention today. Investors should be watching the next two readouts.